Andre Kadima - Academia.edu (original) (raw)

Papers by Andre Kadima

Research paper thumbnail of Peptide-Pulsed Dendritic Cells Following Vaccination with T Cell Response + Primary CD8 Augments the Antigen-Specific Systemic Administration of IL15

Research paper thumbnail of Loss of T cell-mediated antitumor immunity after construct-specific downregulation of retrovirally encoded T-cell receptor expression in vivo

Cancer Gene Therapy, 2009

Research paper thumbnail of Transfer of TCR Genes into Mature T Cells Is Accompanied by the Maintenance of Parental T Cell Avidity

The adoptive transfer of tumor-specific T cells expanded in vitro can be of significant therapeut... more The adoptive transfer of tumor-specific T cells expanded in vitro can be of significant therapeutic value in select cancer patients. This strategy is limited though, as it is often difficult, if not impossible, to obtain T cells of clinical value. The transfer of TCR genes to mature T cells to generate tumor-reactive T cells provides a potential mechanism to overcome

Research paper thumbnail of The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu

Research paper thumbnail of Peptide-Based Cancer Vaccine Vaccination with a Novel after Antigen-Specific T Cell Response Dramatically Enhances the IFN{gamma} Production and Paracrine Release of IL12 Stimulates

Research paper thumbnail of The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu

Research paper thumbnail of Defining the Antigen-Specific T-Cell Response to Vaccination and Poly(I:C)/TLR3 Signaling

Journal of Immunotherapy, 2005

Poly (I:C), a TLR3 ligand, has shown promise as a vaccine adjuvant to CD8 + T cell responses. The... more Poly (I:C), a TLR3 ligand, has shown promise as a vaccine adjuvant to CD8 + T cell responses. The underlying mechanisms involved in creating this adjuvant response in vivo, however, have not been well defined. In this study, we explored the contribution of NK cells and inflammatory cytokines in mediation the poly (I:C) adjuvant effects. Enhanced antigen-specific CD8 +

Research paper thumbnail of Defining the Ability of Cyclophosphamide Preconditioning to Enhance the Antigen-specific CD8+ T-cell Response to Peptide Vaccination: Creation of a Beneficial Host Microenvironment Involving Type I IFNs and Myeloid Cells

Journal of Immunotherapy, 2007

CITATIONS 43 READS 22 7 authors, including: Some of the authors of this publication are also work... more CITATIONS 43 READS 22 7 authors, including: Some of the authors of this publication are also working on these related projects: Investigating circulating tumor cells in general and cancer stem cells in particular in solid and hematological tumors and how it correlate to the immunological and clinical performance View project

Research paper thumbnail of Systemic Administration of IL-15 Augments the Antigen-Specific Primary CD8+ T Cell Response Following Vaccination with Peptide-Pulsed Dendritic Cells

The Journal of Immunology, 2002

CITATIONS 74 READS 25 6 authors, including: Some of the authors of this publication are also work... more CITATIONS 74 READS 25 6 authors, including: Some of the authors of this publication are also working on these related projects: Investigating circulating tumor cells in general and cancer stem cells in particular in solid and hematological tumors and how it correlate to the immunological and clinical performance View project Andre N Kadima

Research paper thumbnail of Review: Novel Nonviral Delivery Approaches for Interleukin-12 Protein and Gene Systems: Curbing Toxicity and Enhancing Adjuvant Activity

Journal of Interferon & Cytokine Research, 2006

It has become increasingly apparent that the ability to generate an optimal host immune response ... more It has become increasingly apparent that the ability to generate an optimal host immune response requires effective cross talk between the innate and adaptive components of the immune system. Pro-inflammatory cytokines, in particular those that can induce a danger signal, often called signal 3, are crucial in this role of initiating and augmenting the presentation of exogenous antigen to T cells by dendritic cells. Interleukin-12 (IL-12) in particular has been defined as a "signal 3" cytokine required for the antigen cross priming. Given this unique interactive function, a significant amount of work has been performed to define possible therapeutic applications for IL-12. Systemic IL-12 administration can clearly act as a potent adjuvant for postvaccination T cell responses in a variety of diseases. As an example, in the cancer setting, systemic IL-12 is capable of suppressing tumor growth, metastasis, and angiogenesis in vivo. IL-12, however, has been associated with significant dose-and schedule-dependent toxicity in early clinical trials, results that have proven to be a major obstacle to its clinical application. Recent research has focused on decreasing the toxicity of IL-12 using different delivery approaches, including virus-based and gene-modified cell-based delivery. Although effective, these approaches also have limitations, including the generation of neutralizing antibodies, in addition to lacking the simplicity and versatility required for universal clinical application. Thus, there is a significant interest in the development of alternative delivery approaches for IL-12 administration that can overcome these issues. Several nonviral delivery approaches for IL-12 protein or gene expression vectors are being defined, including alum, liposomes, and polymer-based delivery. These developing approaches have shown promising adjuvant effects with significantly lessened systemic toxicity. This article discusses the potential capabilities of these nonvirus-based IL-12 delivery systems in different disease settings, including allergy, infection, and cancer. 593

Research paper thumbnail of Peptide-Pulsed Dendritic Cells Following Vaccination with T Cell Response + Primary CD8 Augments the Antigen-Specific Systemic Administration of IL15

Research paper thumbnail of Loss of T cell-mediated antitumor immunity after construct-specific downregulation of retrovirally encoded T-cell receptor expression in vivo

Cancer Gene Therapy, 2009

Research paper thumbnail of Transfer of TCR Genes into Mature T Cells Is Accompanied by the Maintenance of Parental T Cell Avidity

The adoptive transfer of tumor-specific T cells expanded in vitro can be of significant therapeut... more The adoptive transfer of tumor-specific T cells expanded in vitro can be of significant therapeutic value in select cancer patients. This strategy is limited though, as it is often difficult, if not impossible, to obtain T cells of clinical value. The transfer of TCR genes to mature T cells to generate tumor-reactive T cells provides a potential mechanism to overcome

Research paper thumbnail of The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu

Research paper thumbnail of Peptide-Based Cancer Vaccine Vaccination with a Novel after Antigen-Specific T Cell Response Dramatically Enhances the IFN{gamma} Production and Paracrine Release of IL12 Stimulates

Research paper thumbnail of The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu

Research paper thumbnail of Defining the Antigen-Specific T-Cell Response to Vaccination and Poly(I:C)/TLR3 Signaling

Journal of Immunotherapy, 2005

Poly (I:C), a TLR3 ligand, has shown promise as a vaccine adjuvant to CD8 + T cell responses. The... more Poly (I:C), a TLR3 ligand, has shown promise as a vaccine adjuvant to CD8 + T cell responses. The underlying mechanisms involved in creating this adjuvant response in vivo, however, have not been well defined. In this study, we explored the contribution of NK cells and inflammatory cytokines in mediation the poly (I:C) adjuvant effects. Enhanced antigen-specific CD8 +

Research paper thumbnail of Defining the Ability of Cyclophosphamide Preconditioning to Enhance the Antigen-specific CD8+ T-cell Response to Peptide Vaccination: Creation of a Beneficial Host Microenvironment Involving Type I IFNs and Myeloid Cells

Journal of Immunotherapy, 2007

CITATIONS 43 READS 22 7 authors, including: Some of the authors of this publication are also work... more CITATIONS 43 READS 22 7 authors, including: Some of the authors of this publication are also working on these related projects: Investigating circulating tumor cells in general and cancer stem cells in particular in solid and hematological tumors and how it correlate to the immunological and clinical performance View project

Research paper thumbnail of Systemic Administration of IL-15 Augments the Antigen-Specific Primary CD8+ T Cell Response Following Vaccination with Peptide-Pulsed Dendritic Cells

The Journal of Immunology, 2002

CITATIONS 74 READS 25 6 authors, including: Some of the authors of this publication are also work... more CITATIONS 74 READS 25 6 authors, including: Some of the authors of this publication are also working on these related projects: Investigating circulating tumor cells in general and cancer stem cells in particular in solid and hematological tumors and how it correlate to the immunological and clinical performance View project Andre N Kadima

Research paper thumbnail of Review: Novel Nonviral Delivery Approaches for Interleukin-12 Protein and Gene Systems: Curbing Toxicity and Enhancing Adjuvant Activity

Journal of Interferon & Cytokine Research, 2006

It has become increasingly apparent that the ability to generate an optimal host immune response ... more It has become increasingly apparent that the ability to generate an optimal host immune response requires effective cross talk between the innate and adaptive components of the immune system. Pro-inflammatory cytokines, in particular those that can induce a danger signal, often called signal 3, are crucial in this role of initiating and augmenting the presentation of exogenous antigen to T cells by dendritic cells. Interleukin-12 (IL-12) in particular has been defined as a "signal 3" cytokine required for the antigen cross priming. Given this unique interactive function, a significant amount of work has been performed to define possible therapeutic applications for IL-12. Systemic IL-12 administration can clearly act as a potent adjuvant for postvaccination T cell responses in a variety of diseases. As an example, in the cancer setting, systemic IL-12 is capable of suppressing tumor growth, metastasis, and angiogenesis in vivo. IL-12, however, has been associated with significant dose-and schedule-dependent toxicity in early clinical trials, results that have proven to be a major obstacle to its clinical application. Recent research has focused on decreasing the toxicity of IL-12 using different delivery approaches, including virus-based and gene-modified cell-based delivery. Although effective, these approaches also have limitations, including the generation of neutralizing antibodies, in addition to lacking the simplicity and versatility required for universal clinical application. Thus, there is a significant interest in the development of alternative delivery approaches for IL-12 administration that can overcome these issues. Several nonviral delivery approaches for IL-12 protein or gene expression vectors are being defined, including alum, liposomes, and polymer-based delivery. These developing approaches have shown promising adjuvant effects with significantly lessened systemic toxicity. This article discusses the potential capabilities of these nonvirus-based IL-12 delivery systems in different disease settings, including allergy, infection, and cancer. 593